Ticker Launch
Sign inTry it free

IPO · BCYC

Bicycle Therapeutics PLC

Formerly BICYCLE THERAPEUTICS Ltd

Bicycle Therapeutics PLC (BCYC) priced its initial public offering on May 23, 2019 at $14.00 per ADS, raising $60.7M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $247.7M. Goldman Sachs was lead-left underwriter, joined by Jefferies and Canaccord Genuity. Goodwin Procter advised the company and Cooley advised the underwriters.

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a class of medicines called Bicycles, which are fully synthetic short peptides constrained into two loops. It uses a phage display screening platform and targets diseases underserved by existing therapeutics.

Status
IPO
Ticker
BCYC
Exchange
Nasdaq Global Select
Priced
May 23, 2019
IPO price
$14.00 per ADS
Raised
$60.7M
Market cap at IPO price
$247.7M
First filed
Apr 26, 2019
Underwriters
Goldman Sachs, Jefferies and Canaccord Genuity
Company counsel
Goodwin Procter
Underwriters' counsel
Cooley
Sector
Biotech & pharma
Country / state
United Kingdom

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.

More on this listing for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other Biotech & pharma IPOs in 2019